Cover Image
市場調查報告書

肺氣腫:開發中產品分析

Emphysema - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200444
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
肺氣腫:開發中產品分析 Emphysema - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 48 Pages
簡介

肺氣腫是長期、進行性的肺部疾病。特徵是肺泡(肺內部的氣囊)的過度膨脹使呼吸急促等。這個疾病的情況,是由於氣體交換(氧和二氧化碳)相關肺組織的破壞,肺泡外邊的氣體運動緩慢化或停止,呼氣的流動變慢停止。還有肺氣腫也是慢性阻塞性肺病(COPD)的一種。抽煙成為肺氣腫的一般原因。治療方法有吸入器,氧,藥物治療,以及偶爾有進行外科手術緩和症狀等。

本報告提供全球各國的肺氣腫治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等。

簡介

  • 調查範圍

肺氣腫概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肺氣腫:企業開發中的治療藥

肺氣腫:大學/機關研究中的治療藥

肺氣腫:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肺氣腫:企業開發中的產品

肺氣腫:大學/機關研究中的產品

肺氣腫的治療藥開發企業

  • Abeona Therapeutics, Inc.
  • Angion Biomedica Corp.
  • ProMetic Life Sciences Inc.
  • rEVO Biologics, Inc.

肺氣腫:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肺氣腫:最近的開發平台趨勢

肺氣腫:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8515IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Emphysema - Pipeline Review, H2 2016, provides an overview of the Emphysema (Respiratory) pipeline landscape.

Emphysema is a type of COPD involving damage to the alveoli in the lungs. Symptoms include shortness of breath and cough with sputum. Risk factors include age, smoking, exposure to air pollutions, factory fumes, coal and silica dust. Treatment includes bronchodilators, antibiotics and steroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Emphysema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Emphysema (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Emphysema (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Emphysema.

Emphysema (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Emphysema (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Emphysema (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Emphysema (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Emphysema (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Emphysema (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Emphysema (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Emphysema (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Emphysema Overview
  • Therapeutics Development
    • Pipeline Products for Emphysema - Overview
    • Pipeline Products for Emphysema - Comparative Analysis
  • Emphysema - Therapeutics under Development by Companies
  • Emphysema - Therapeutics under Investigation by Universities/Institutes
  • Emphysema - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Emphysema - Products under Development by Companies
  • Emphysema - Products under Investigation by Universities/Institutes
  • Emphysema - Companies Involved in Therapeutics Development
    • Angion Biomedica Corp.
    • ProMetic Life Sciences Inc.
    • rEVO Biologics, Inc.
    • SATT North SAS
    • TGV-Laboratories
  • Emphysema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Emphysema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDO-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit EMAP II for Emphysema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit Beta Galactosidase for Pulmonary Emphysema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Human Alpha-1 Antitrypsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Emphysema - Dormant Projects
  • Emphysema - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Emphysema, H2 2016
  • Number of Products under Development for Emphysema - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Emphysema - Pipeline by Abeona Therapeutics, Inc. , H2 2016
  • Emphysema - Pipeline by Angion Biomedica Corp., H2 2016
  • Emphysema - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Emphysema - Pipeline by rEVO Biologics, Inc., H2 2016
  • Emphysema - Pipeline by SATT North SAS, H2 2016
  • Emphysema - Pipeline by TGV-Laboratories, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Emphysema - Dormant Projects, H2 2016
  • Emphysema - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Emphysema, H2 2016
  • Number of Products under Development for Emphysema - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top